Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of CYT003-QbG10 in adult patients with house dust mite allergic rhinoconjunctivitis
2008-004639-39Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Aug 2008
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CYT003-QbG10 in allergic rhinoconjunctivitis (ARC) and house dust mite allergy (3 arms), sponsored by Cytos Biotechnology AG. Primary endpoint: Primary: Rhinoconjunctivitis symptom and medication scores over 2 weeks. Started Aug 2008; status: completed.
02
Drugs
CYT003-QbG10
03
Conditions
allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2008-004639-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004639-39.